[Skip to Content]
[Skip to Content Landing]
March 28, 2007

Pioglitazone vs Glimepiride and Carotid Intima-Media Thickness

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;297(12):1315-1317. doi:10.1001/jama.297.12.1315

To the Editor: The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) trial by Dr Mazzone and colleagues1 found a reduced progression of carotid artery intima-media thickness (CIMT) in patients with type 2 diabetes mellitus taking pioglitazone for 18 months, compared with those taking glimepiride. There was no regression of CIMT in either treatment group.

First Page Preview View Large
First page PDF preview
First page PDF preview